Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Gilead Sciences
GILDHealthcareGenerated Aug 19, 2026, 10:34 PM UTC
GILD (Gilead Sciences) analytical snapshot. Revenue grew +2.4% YoY to $29.44B. 5-year revenue CAGR +1.5%; 10y CAGR -0.4%. Net margin at 28.90% (expanding ▲). Market cap $183.02B at $147.60 per share. Trailing P/E 21.77, P/S 6.22, P/B 15.47. EV/Operating income ≈ 20.34 (EV $203.85B). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score 8 (data confidence 83%). Descriptive analytics from public filings — not investment advice.
Free SEC analysis
— computed from SEC filings, free to readFilings & Ownership
Latest annual report (10-K) filed Feb 24, 2026. Latest quarterly report (10-Q) filed Aug 6, 2026. 7 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 24, 2026.
- Latest quarterly report (10-Q) filed Aug 6, 2026.
- 7 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Gilead Sciences; broad institutional reporting.
- Recent filers include SPHINX TRADING, LP, SPHINX TRADING, LP, Axiom Investment Management LLC.
- 7 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 13 recent 13G passive institutional ownership notices.
| Filer | Form | Filed |
|---|---|---|
| SPHINX TRADING, LP | 13F-HR | Feb 9, 2015 |
| SPHINX TRADING, LP | 13F-HR | Feb 6, 2015 |
| Axiom Investment Management LLC | 13F-HR | Aug 15, 2022 |
| PASSPORT MANAGEMENT LLC | 13F-HR | Feb 15, 2006 |
| MUHLENKAMP & CO INC | 13F-HR | May 17, 2017 |
| Date | Form | Description |
|---|---|---|
| Aug 4, 2026 | 8-K | FORM 8-K |
| May 20, 2026 | 8-K | FORM 8-K |
| May 7, 2026 | 8-K | FORM 8-K |
| May 4, 2026 | 8-K | FORM 8-K |
| Apr 28, 2026 | 8-K | FORM 8-K |
| Feb 23, 2026 | 8-K | FORM 8-K |
| Feb 10, 2026 | 8-K | FORM 8-K |
SEC Filing Deep-Analysis
2 risk signal(s), 1 watch item(s) detected from XBRL filing diff analysis. 2 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- Earnings-cash flow divergence: Net income grew +1672.9% while operating cash flow declined -7.5%. This divergence may indicate accrual-based earnings inflation — non-cash gains, aggressive revenue recognition, or working capital absorption. The accrual ratio (NI − OCF) is deteriorating.
- Restatement of financial statements: The term "restatement of" "previously issued" appears in 1 recent filing(s) (vs 1 in the prior period). This risk language is ongoing.
- NEW: Off-balance sheet arrangements: Off-balance sheet arrangements appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- Endogenous analysis: 2 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- 4 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 1 new risk-language term(s) detected in filing text: Off-balance sheet arrangements.
- Ongoing high-severity risk language: Restatement of financial statements.
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $28.75B | $29.44B | $689.0M | +2.4% |
| Gross profit | $5.35B | $5.93B | $578.0M | +10.8% |
| Operating income | $1.66B | $10.02B | $8.36B | +503.0% |
| Net income | $480.0M | $8.51B | $8.03B | +1672.9% |
| Operating cash flow | $10.83B | $10.02B | $-809.0M | -7.5% |
| Capex | $523.0M | $563.0M | $40.0M | +7.6% |
| Total assets | $58.99B | $59.02B | $28.0M | +0.0% |
| Long-term debt | $26.71B | $24.94B | $-1.77B | -6.6% |
| Cash & equivalents | $9.99B | $7.56B | $-2.43B | -24.3% |
| Stockholders equity | $19.33B | $22.70B | $3.37B | +17.4% |
| Inventory | $1.71B | $1.77B | $64.0M | +3.7% |
| Accounts receivable | $4.42B | $4.91B | $493.0M | +11.2% |
| R&D expense | $5.02B | $9.11B | $4.09B | +81.5% |
| SG&A expense | $6.09B | $5.77B | $-317.0M | -5.2% |
| Interest expense | $935.0M | $944.0M | $9.0M | +1.0% |
| Type | Concepts |
|---|---|
| Added | AssetsFairValueDisclosure, LiabilitiesFairValueDisclosure, OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent, OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent |
| Removed | AccruedIncomeTaxesCurrent, AdvertisingExpense, AllocatedShareBasedCompensationExpense, AllocatedShareBasedCompensationExpenseNetOfTax, AmortizationOfIntangibleAssets, AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost, AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue, BuildingsAndImprovementsGross, CapitalizedComputerSoftwareGross, ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest |
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Restatement of financial statements | high | 1 | 1 | Ongoing |
| Impairment charge | medium | 5 | 8 | Ongoing |
| Restructuring | medium | 5 | 4 | Ongoing |
| Off-balance sheet arrangements | medium | 5 | 0 | NEW |
| Related party transactions | low | 5 | 5 | Ongoing |
Fundamentals
Revenue grew +2.4% YoY to $29.44B. 5-year revenue CAGR +1.5%; 10y CAGR -0.4%. Net margin at 28.90% (expanding ▲).
- Revenue grew +2.4% YoY to $29.44B.
- 5-year revenue CAGR +1.5%; 10y CAGR -0.4%.
- Net margin at 28.90% (expanding ▲).
- Return on equity 37.48%, ROA 14.42%, ROIC 21.04%.
- Gross margin 0.00%, operating margin 34.04%.
- Free cash flow margin 32.12% ($9.46B).
- Net income up ▲ +1672.9% YoY.
- Debt/equity 2.22, current ratio 1.27, net debt $20.83B.
- Asset turnover 0.60 — capital efficiency.
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2024 | $28.75B | +6.0% | 0.00 | 5.78 | 1.67 | $10.30B | 2.48 |
| 2025 | $29.44B | +2.4% | 0.00 | 34.04 | 28.90 | $9.46B | 37.48 |
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Mar 31, 2019 | $5.28B | +3.8% | — | 37.40% |
| Jun 30, 2019 | $5.68B | +0.7% | +7.7% | 33.07% |
| Sep 30, 2019 | $5.60B | +0.1% | -1.4% | -20.79% |
| Mar 31, 2020 | $5.55B | +5.1% | -1.0% | 27.96% |
| Jun 30, 2020 | $5.14B | -9.5% | -7.3% | -64.92% |
| Sep 30, 2020 | $6.58B | +17.4% | +27.9% | 5.47% |
Pro analysis — preview
— score, signals & key metrics shown; full reasoning lockedValuation
Market cap $183.02B at $147.60 per share. Trailing P/E 21.77, P/S 6.22, P/B 15.47. EV/Operating income ≈ 20.34 (EV $203.85B).
- Market cap $183.02B at $147.60 per share.
Price & Technicals
Price $147.60 — uptrend (above 200-DMA); 1-month momentum positive. RSI(14) 79.63 (overbought).
- Price $147.60 — uptrend (above 200-DMA); 1-month momentum positive.
Macro & Rates
Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.71%.
- Market regime: Risk-on · Supportive.
Risk Scorecard
Composite risk Elevated. Leverage debt/equity 2.22 (high). Liquidity current ratio 1.27 (adequate).
- Composite risk: Elevated.
See the full picture behind every stock
Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.
3 sections free · 4 Pro previews · composite 8
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Gilead Sciences is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Analytical read
deterministic previewRevenue grew **+2.4%** YoY to $29.44B..
Peer comparison
Defensive groupHow GILD stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| DexCom Inc. DXCM | 19 | Neutral |
| Bristol-Myers Squibb BMY | 19 | Neutral |
| Eli Lilly & Co. LLY | 17 | Neutral |
| HCA Healthcare HCA | 9 | Neutral |
| Gilead Sciences GILD● you | 8 | Neutral |
| Johnson & Johnson JNJ | 8 | Neutral |
| Abbott Laboratories ABT | 7 | Neutral |
| Biogen Inc. BIIB | 7 | Neutral |
| Intuitive Surgical Inc. ISRG | 7 | Neutral |
| Coca-Cola Co. KO | 6 | Neutral |
| Zoetis Inc. ZTS | 6 | Neutral |
| Thermo Fisher Scientific TMO | 3 | Neutral |
| Regeneron Pharmaceuticals REGN | 3 | Neutral |
| Danaher Corp. DHR | 1 | Neutral |
| Merck & Co. MRK | 0 | Neutral |
| Illumina Inc. ILMN | 0 | Neutral |
| Colgate-Palmolive CL | -2 | Neutral |
| Vertex Pharmaceuticals VRTX | -2 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Procter & Gamble PG | -7 | Neutral |
| CVS Health Corp. CVS | -8 | Neutral |
| Walmart Inc. WMT | -8 | Neutral |
| Mondelez International MDLZ | -10 | Neutral |
| Amgen Inc. AMGN | -10 | Neutral |
| Cigna Group CI | -11 | Neutral |
| Kroger Co. KR | -12 | Neutral |
| Costco Wholesale COST | -14 | Neutral |
| Pfizer Inc. PFE | -15 | Neutral |
| PepsiCo Inc. PEP | -16 | Neutral |
| Sysco Corp. SYY | -16 | Neutral |
| Hershey Co. HSY | -17 | Neutral |
| Kimberly-Clark Corp. KMB | -18 | Neutral |
| Moderna Inc. MRNA | -21 | Neutral |
| UnitedHealth Group UNH | -25 | Neutral |